A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
暂无分享,去创建一个
R. Reznek | W. Gregory | M. Slevin | P. Clark | S. Joel | R. Osborne | D. Talbot | P. Johnson | T. Masud | P. Wrigley | P I Clark | M L Slevin | S P Joel | R J Osborne | D I Talbot | P W Johnson | R Reznek | T Masud | W Gregory | P F Wrigley
[1] W. Evans,et al. Altered protein binding of etoposide in patients with cancer , 1989, Clinical pharmacology and therapeutics.
[2] W. Evans,et al. Relation of systemic exposure to unbound etoposide and hematologic toxicity , 1991, Clinical pharmacology and therapeutics.
[3] M. Slevin,et al. High-performance liquid chromatography of etoposide in plasma and urine. , 1985, Journal of chromatography.
[4] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[5] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[6] M. D’Incalci,et al. In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma. , 1982, European journal of cancer & clinical oncology.
[7] D G Lowe,et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Partial Cross-Resistance of Cultured Murine Leukemia Vincristine-Resistant P388 Cells to 4′-Demethylepipodophyllotoxin Ethylidene-β-D-Glucoside 1 , 1980, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[9] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[10] J. Ducore,et al. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. , 1983, Cancer research.
[11] M. Slevin,et al. Variable bioavailability following repeated oral doses of etoposide. , 1985, European journal of cancer & clinical oncology.
[12] P. Willcox,et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. , 1991, European journal of cancer.
[13] A. Krishan,et al. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts , 1975, The Journal of cell biology.
[14] J. Haybittle. The reporting of non-significant results in clinical trials , 1979 .
[15] D. Cox. Regression Models and Life-Tables , 1972 .
[16] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[17] B. Barlogie,et al. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. , 1976, Cancer treatment reports.